Infliximab subcutaneous + Immunosuppressive Agents

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Inflammatory Disease

Conditions

Inflammatory Disease, Disease Crohn, Bowel Disease

Trial Timeline

Nov 25, 2021 → Dec 1, 2025

NCT ID

NCT06059989

About Infliximab subcutaneous + Immunosuppressive Agents

Infliximab subcutaneous + Immunosuppressive Agents is a phase 3 stage product being developed by Celltrion for Inflammatory Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06059989. Target conditions include Inflammatory Disease, Disease Crohn, Bowel Disease.

What happened to similar drugs?

10 of 20 similar drugs in Inflammatory Disease were approved

Approved (10) Terminated (3) Active (10)

✅Infliximab + Infliximab + InfliximabCelltrionApproved

✅fidaxomicinAstellas PharmaApproved

✅RisankizumabAbbVieApproved

✅Human Papillomavirus VaccineMerckApproved

✅BezlotoxumabMerckApproved

✅Celecoxib + Ibuprofen plus OmeprazolePfizerApproved

✅Alemtuzumab infusionSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06059989	Phase 3	Recruiting	Nov 25, 2021	Dec 1, 2025	Inflammatory Disease

Competing Products

20 competing products in Inflammatory Disease

See all competitors

Product	Company	Stage	Hype Score
Infliximab + Infliximab + Infliximab	Celltrion	Approved	50
CT-P13	Celltrion	Phase 3	36
Subcutaneous infliximab CT-P13 Remsima®SC	Celltrion	Pre-clinical	22
fidaxomicin	Astellas Pharma	Approved	43
Eribulin + Adriamycin + Cyclophosphamide	Eisai	Phase 2	39
E6007 + E6007 + E6007 + E6007 + E6007 + E6007	Eisai	Phase 1	29
Placebo + MORF-057	Eli Lilly	Phase 2	42
Baricitinib + Baricitinib	Eli Lilly	Phase 2	35
LY3114062 SC + Placebo + LY3114062 IV	Eli Lilly	Phase 1	29
MORF-057 + Placebo	Eli Lilly	Phase 2	39
MORF-057	Eli Lilly	Phase 2	35
LY3009104	Eli Lilly	Phase 1	29
HRF2105 patch + Loxoprofen patch + placebo	Jiangsu Hengrui Medicine	Phase 2	31
Risankizumab	AbbVie	Approved	43
GC012F Injection infusion	AstraZeneca	Phase 1	36
AZD6793 + Placebo	AstraZeneca	Phase 1	29
Human Papillomavirus Vaccine	Merck	Approved	43
Pembrolizumab	Merck	Phase 2	31
Gardasil vaccine	Merck	Pre-clinical	26
Bezlotoxumab	Merck	Approved	35